Share This Page
Drugs in ATC Class P01BD
✉ Email this page to a colleague
Drugs in ATC Class: P01BD - Diaminopyrimidines
| Tradename | Generic Name |
|---|---|
| DARAPRIM | pyrimethamine |
| PYRIMETHAMINE | pyrimethamine |
| FANSIDAR | pyrimethamine; sulfadoxine |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class P01BD (Diaminopyrimidines): What’s protected, when exclusivity ends, and where generics or biosimilars face risk
ATC P01BD (diaminopyrimidines) covers a small set of antiprotozoals used primarily for malaria. Commercial leverage and litigation risk concentrate in the few originators with (1) active-ingredient patents, (2) combination fixed-dose form (FDC) and co-pack IP, and (3) dosing-regimen method-of-use claims. Patent strength is most often driven by formulation and process claims for orally administered tablets/capsules and by regulatory exclusivities that can delay generic entry even after primary compound patents expire. The patent estate and entry risk are highly product-specific within the class.
Bottom line for investors and licensing teams: map IP to each marketed SKU in P01BD (not the class as a whole), then overlay Orange Book (U.S.) and equivalent national registers for (a) earliest expiry by claim family, (b) last listed Orange Book patent, and (c) any Paragraph IV filings or settlements. Without that SKU-level mapping, class-wide conclusions do not support actionable freedom-to-operate (FTO), licensing valuation, or launch timing.
Which diaminopyrimidines are in ATC P01BD, and what is the commercial footprint by active ingredient?
Featured-snippet answer: ATC P01BD is the antimalarial subclass “diaminopyrimidines.” The practical commercial market is driven by specific branded actives and their fixed-dose or line-extension combinations.
What diaminopyrimidines typically sit in P01BD in practice
In most jurisdictions, the subclass is used to group diaminopyrimidine antimalarials, which commonly include:
- Pyrimethamine (diaminopyrimidine antimalarial; often used in combination therapy)
- Other diaminopyrimidine derivatives used as antimalarials in certain markets, depending on national ATC implementations
Market dynamics that matter for P01BD
Even for a smaller therapeutic class, P01BD drugs face recurring dynamics:
1) Combination strategy drives FDC IP Originators often protect:
- FDC tablet formulations
- Co-administration dosing regimens
- Stability and dissolution profiles that support biowaiver or bioequivalence strategies
2) Procurement and tender cycles affect launch economics Generic uptake in malaria is often supply-chain and procurement driven, not prescription preference driven. Post-exclusivity generic entry can be fast once price and supply stabilize.
3) Public health registration pathways shape timelines Regulatory packages for generics (especially for low-cost procurement markets) can be streamlined, increasing the chance that the first generic can file at or near patent expiry.
What patents protect diaminopyrimidine antimalarials (P01BD) in the US and EU?
Featured-snippet answer: IP around P01BD products usually concentrates in compound (active), combination, and formulation/process claim families, then in method-of-use (dosing) patents. The relative importance varies by product.
Typical patent claim clusters
Patent estates for P01BD antimalarials commonly include these clusters:
Active ingredient (compound) patents
- New diaminopyrimidine chemical entities
- Salts and polymorphs (if they are treated as distinct inventions)
- Crystal forms and particle-size distributions affecting solubility
Fixed-dose combinations and regimen patents
- Claims directed to co-formulations with partner antimalarials
- Claims to specific dosing schedules (method-of-use)
- Claims covering pediatric regimens and weight-band dosing
Formulation and manufacturing patents
- Tablet compression parameters, granulation, and milling
- Dissolution specification windows and excipient selection
- Stability-indicating formulations for shelf-life extension
Jurisdictional differences you see in enforcement
- US: Orange Book listing drives Hatch-Waxman leverage. Paragraph IV filings determine litigation posture and automatic stays.
- EU: Enforcement relies on national designation of the European patent and local regulatory exclusivities. Supplementary Protection Certificates (SPCs) can extend protection for time-limited periods tied to marketing authorization.
When does exclusivity end for diaminopyrimidine antimalarials, and how does that differ from patent expiration?
Featured-snippet answer: Exclusivity can end later than patent expiry due to pediatric-related extensions, SPCs in Europe, and regulatory exclusivity in the US. In practice, “last Orange Book patent expiration” is the key metric for generic entry timing in the US.
US exclusivity vs patent expiry (what delays generics)
For US-made entry planning, the timeline usually separates into:
- Patent expiry (compound or formulation claims expire on a date driven by filing priority and term rules)
- Regulatory exclusivity (rarely a substitute for listed patents, but it can block approval)
- Orange Book listed patent expiry (the controlling legal trigger for ANDA timing under Hatch-Waxman)
EU exclusivity levers
- SPC: Extends patent protection for time-limited periods after marketing authorization
- Data exclusivity / market exclusivity: Applies at the regulatory dossier level and is typically tied to first authorization
What is the Orange Book status of P01BD diaminopyrimidine products, and which patents are listed?
Featured-snippet answer: Orange Book status is SKU-specific. A class label (P01BD) does not map cleanly to a single Orange Book record.
What to extract from Orange Book for P01BD workstreams
For each marketed product containing a diaminopyrimidine active (and any FDCs), the highest-value extraction fields are:
- Drug product active ingredient(s)
- Dosage form and route
- Sponsor/holder
- “Patent number” and “expiration date”
- Whether patents are “method of use,” “formulation,” or “composition”
- Whether the patent is “certified” against by generic applicants (Paragraph IV)
How to use Orange Book listings operationally
- Build a “last listed patent expiration” table per SKU
- Identify which listed patents are formulation/process vs method-of-use
- Track any pending ANDA litigation attached to each listed patent
(Doing this correctly requires SKU names and Orange Book listing records. A class-level answer cannot support litigation-grade launch timelines.)
How many patents cover diaminopyrimidine formulations and dosing regimens, and which types tend to be most vulnerable?
Featured-snippet answer: Most estates contain multiple overlapping families. Formulation and method-of-use claims are frequently the most contested in generic challenges, while compound claims often remain durable but are fewer in number.
Estate composition patterns seen across antimalarial small molecules
- Formulation family count: often higher due to lifecycle management (stability, bioavailability, pediatric adaptation)
- Method-of-use: sometimes concentrated around specific combination schedules or patient stratification
- Process claims: can survive longer if tied to manufacturing innovations rather than routine scale-up
Common vulnerability themes
- Over-broad regimen claims that fail enablement or lack novelty
- Formulation claims with limited distinguishing features over prior art excipient systems
- Salt/polymorph claims when solid-state features are not clearly tied to technical effect
What patent litigation affects diaminopyrimidine (P01BD) generic entry, including Paragraph IV challenges and settlements?
Featured-snippet answer: Paragraph IV challenges drive the litigation and stay structure in the US; settlement agreements often shift the launch date to a “carve-out” that matches the earliest non-infringed listed patent or a negotiated entry window. Litigation is again SKU-specific.
Typical litigation mechanics for P01BD antimalarials
- ANDA filers certify against Orange Book listed patents: Paragraph IV (invalidity or non-infringement)
- Patent holders sue within statutory time to trigger a stay
- Settlements can include:
- agreed launch dates
- stipulations on non-infringement
- covenant-not-to-sue boundaries around specific NDCs/dosage forms
What business teams track
- Whether the case targets formulation or method-of-use patents
- Whether the court invalidates key claims or narrows construction
- Whether subsequent Orange Book listings “reshape” the stay landscape
How does ATC P01BD diaminopyrimidine patent strength compare across active ingredients and fixed-dose combinations?
Featured-snippet answer: Patent strength correlates more with lifecycle management (FDC and formulation) than with the base active ingredient alone. For P01BD products, the strongest estates often belong to FDC SKUs.
Comparison framework for decisioning
A robust comparison table for P01BD should include per SKU:
- Earliest compound expiry date
- Last formulation expiry date
- Last method-of-use expiry date
- Last Orange Book listed patent expiry date
- Known litigation status (active, stayed, settled)
- Any SPC in EU and its expiry window
A class label cannot substitute for this SKU-level dataset.
What formulations are protected for diaminopyrimidines, and what manufacturing/IP barriers exist for generics?
Featured-snippet answer: Protected formulations are often tied to tablet/capsule composition, dissolution parameters, stability specifications, and manufacturing processes that affect particle size and bioavailability. These can create non-infringement and regulatory hurdles for generic process design.
Formulation-protection targets that matter in generic design
- Excipients and ratios that achieve specific dissolution profiles
- Solid-state form control (polymorph/salt selection)
- Granulation and compression parameter windows
- Stability-indicating formulation choices that lock in shelf-life performance
Manufacturing/IP barriers that show up in disputes
- Infringement theories focused on “substantially the same” process outcomes
- Counterarguments based on different critical process parameters or different particle-size distribution
- Separate patent families for process vs composition, requiring multi-dimensional FTO
Which companies control the diaminopyrimidine patent estate and supply chain in key markets?
Featured-snippet answer: Control typically sits with originator pharma for branded tablets and with generic incumbents once patent barriers fall. Exact holders vary by SKU and geography.
How to structure a holder map for P01BD
For each SKU that is in P01BD in major markets, build a company map with:
- Patent assignees (primary and continuations)
- Marketing authorization holders
- Orange Book listing holders (US)
- Likely generic challengers (first-to-file ANDA makers)
Without the SKU list and register pulls, an accurate company-by-company mapping cannot be produced.
What generic entry risks exist for diaminopyrimidines after patent expiry?
Featured-snippet answer: The biggest generic entry risks are (1) remaining listed patents beyond the base compound expiry date, (2) active litigation affecting at least one listed patent, and (3) settlements that delay launch despite earlier compound expiry. Manufacturing IP barriers can also raise redesign costs.
Scenario logic
Generic entry planning should be built around:
- “Last listed patent expiry” as the launch ceiling in the US
- Whether a Paragraph IV settlement delays launch to a negotiated date
- Whether the generic product is forced to avoid certain NDC strengths/dosage forms due to claim scope
What does the biosimilar risk look like for P01BD diaminopyrimidines?
Featured-snippet answer: Biosimilar risk is not a relevant construct for small-molecule diaminopyrimidine antimalarials. The IP and entry pathway concerns are generic (ANDA/MAA equivalents), not biologics.
Key takeaways
- ATC P01BD diaminopyrimidines is a small antimalarial subclass; commercial and patent dynamics are driven by SKU-level product composition and lifecycle management, especially FDC and formulation.
- In the US, generic entry timing is best modeled by Orange Book “last listed patent expiration” plus the litigation/settlement posture attached to those patents.
- Patent estates for P01BD antimalarials most often cluster into compound, combination/regimen, and formulation/process families; generic design must clear infringement risk across each cluster where claims are asserted.
- EU protection can be extended via SPCs, shifting the effective exclusivity window beyond base patent expiry.
- Biosimilar frameworks do not apply; the relevant competitive risk is generic entry timing and IP barrier clearance.
FAQs
-
How do I estimate the earliest US generic launch date for a P01BD diaminopyrimidine?
Use the last Orange Book listed patent expiration for the relevant NDC strength/dosage form and overlay any Paragraph IV litigation or settlement dates. -
Which patent types most commonly get challenged for antimalarial small-molecule generics?
Formulation and method-of-use/regimen patents are frequently targeted because they can be more contested on claim construction and obviousness over prior art formulation/regimen work. -
Can formulation patents delay generic entry even after compound patent expiry?
Yes. If formulation/process patents are separately listed in the Orange Book, they can control approval timing even when the active compound patent expires. -
What settlement terms most often affect launch timing in Hatch-Waxman cases for small molecules?
Settlements often include agreed launch dates, covenants not to sue for specific products/NDCs, and sometimes stipulations that narrow dispute scope. -
Do diaminopyrimidines face biosimilar competition risk?
No. P01BD diaminopyrimidines are small molecules, so the relevant pathway is generic approval rather than biosimilar development.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- European Medicines Agency. (n.d.). Supplementary protection certificates (SPC). European Medicines Agency.
- U.S. Code. (n.d.). 35 U.S.C. § 156 and Hatch-Waxman provisions (ANDA/PAR IV framework). Cornell Law School.
More… ↓
